(j) Alternative Methods of Compliance (AMOCs)

The Manager, International Validation Branch, FAA, has the authority to approve AMOCs for this AD, if requested using the procedures found in 14 CFR 39.19. In accordance with 14 CFR 39.19, send your request to your principal inspector or local Flight Standards District Office, as appropriate. If sending information directly to the manager of the International Validation Branch, send it to the attention of the person identified in paragraph (k) of this AD and email to: *AMOC@faa.gov.* Before using any approved AMOC, notify your appropriate principal inspector, or lacking a principal inspector, the manager of the local flight standards district office/certificate holding district office.

(k) Additional Information

For more information about this AD, contact Peter Schmitt, Aviation Safety Engineer, FAA, 1600 Stewart Avenue, Suite 410, Westbury, NY 11590; phone: (206) 231–3377; email: *peter.a.schmitt@faa.gov.*

(l) Material Incorporated by Reference

(1) The Director of the Federal Register approved the incorporation by reference (IBR) of the material listed in this paragraph under 5 U.S.C. 552(a) and 1 CFR part 51.

(2) You must use this material as applicable to do the actions required by this AD, unless the AD specifies otherwise.

(i) SCHEMPP–HIRTH Flugzeugbau GmbH Technical Note No. 278–25, Revision 1, dated July 9, 2024.

(ii) [Reserved]

(3) For SCHEMPP–HIRTH Flugzeugbau GmbH material identified in this AD, contact Schempp-Hirth Flugzeugbau GmbH, Krebenstraße 25, 73230 Kirchheim unter Teck, Germany; phone: +49 7021 7298–0; email: *info@schempp-hirth.com;* website: *schempp-hirth.com.*

(4) You may view this material at the FAA, Airworthiness Products Section, Operational Safety Branch, 901 Locust, Kansas City, MO 64106. For information on the availability of this material at the FAA, call (817) 222–5110.

(5) You may view this material at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, visit *www.archives.gov/federal-register/cfr/ibr-locations* or email *fr.inspection@nara.gov.*

Issued on January 28, 2026.

Steven W. Thompson,

Acting Deputy Director, Compliance & Airworthiness Division, Aircraft Certification Service.

[FR Doc. 2026–04348 Filed 3–4–26; 8:45 am]

BILLING CODE 4910–13–P

DEPARTMENT OF COMMERCE

15 CFR Part 4

[Docket No. 260107–0008]

RIN 0605–AA84

Updating and Streamlining the Department of Commerce's Privacy Act Regulations; Correction

AGENCY: Office of the Secretary, Department of Commerce (Department).

ACTION: Correcting amendment.

SUMMARY: By this action, the Department makes a correcting amendment to its Privacy Act regulations. The Department previously amended those regulations via final rule by, among other things, updating eighteen references to an outdated Department position title. The amendatory instructions set forth in that rule, however, omitted mention of two of the paragraphs amended in such way. This action merely corrects that omission and does not make any further changes to the regulations.

DATES: The rule is effective March 5, 2026.

FOR FURTHER INFORMATION CONTACT: Daniel Sweeney, Senior Counsel, Office of the General Counsel, at (202) 482–1395.

SUPPLEMENTARY INFORMATION: On February 17, 2026, the Department issued a final rule amending 15 CFR part 4 by, among other things, updating eighteen references to an outdated Department position title (91 FR 7115). Twelve of those references were in § 4.29, spread across paragraphs (b), (c), (e), (g), (h), and (i). Although the February 17, 2026 final rule intended to amend all of the references in § 4.29, the relevant amendatory instruction—instruction 5—omitted mention of paragraphs (h) and (i). This action corrects that omission to properly reflect the amendments to § 4.29 for the reasons stated in the February 17, 2026 final rule. This action does not make any other changes to part 4.

Regulatory Classifications

A. Administrative Procedure Act

Pursuant to 5 U.S.C. 553(b)(B), the Department finds good cause to waive the prior notice and opportunity for public participation requirements of the Administrative Procedure Act for this action. The Department considers this action to be uncontroversial, and has determined that prior notice and opportunity for public participation is unnecessary, because this action only corrects an omission in the language of an amendatory instruction; this correction will ensure that the amendatory instructions properly reflect the amendments made by the rule. For the same reason, the Department has determined that delaying the effectiveness of this corrective action would be contrary to the public interest; this action will correct an omission and remove a potential source of confusion without introducing any new cost for the public. The Department therefore finds good cause to waive the public notice and comment period under 553(b)(B) and to waive the 30-day delay in effectiveness under 553(d).

B. Executive Orders 12866, 14192, and 13132

This rule is not significant pursuant to Executive Order (E.O.) 12866. This rule is an E.O. 14192 deregulatory action. This rule does not contain policies having federalism implications as the term is defined in E.O. 13132.

C. Regulatory Flexibility Act

Because a notice of proposed rulemaking and an opportunity for public participation are not required to be given for this rule by 5 U.S.C. 553(b)(B), the analytical requirements of the Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*) are not applicable. Accordingly, no regulatory flexibility analysis is required, and none has been prepared.

D. Paperwork Reduction Act

This rule will not impose additional reporting or recordkeeping requirements under the Paperwork Reduction Act of 1995, 44 U.S.C. 3501, *et seq.*

List of Subjects in 15 CFR Part 4

Administrative practice and procedure, Archives and records, Freedom of information, Penalties, Privacy.

Dated: March 2, 2026.

Pierre Gentin,

General Counsel of the U.S. Department of Commerce.

For the reasons set forth above, part 4 of title 15 of the Code of Federal Regulations is amended by making the following correcting amendments:

PART 4—DISCLOSURE OF GOVERNMENT INFORMATION

■ 1. The authority citation for part 4 continues to read as follows:

Authority: 5 U.S.C. 301; 5 U.S.C. 552; 5 U.S.C. 552a; 5 U.S.C. 553; 31 U.S.C. 3717; 44 U.S.C. 3101; Reorganization Plan No. 5 of 1950.

Subpart B—Privacy Act

■ 2. Amend § 4.29 by revising paragraphs (h) and (i) to read as follows:

§ 4.29 Appeal of initial adverse agency determination on correction or amendment.

* * * * *

(h) In making the final determination, the Assistant General Counsel for Employment, Litigation and Information, or in the case of an initial denial by the Office of the Inspector General, the Counsel to the Inspector General, shall employ the criteria set forth in § 4.28(c) and shall deny an appeal only on grounds set forth in § 4.28(e).

(i) If an appeal is partially granted and partially denied, the Assistant General Counsel for Employment, Litigation and Information, or in the case of an initial denial by the Office of the Inspector General, the Counsel to the Inspector General, shall follow the appropriate procedures of this section as to the records within the grant and the records within the denial.

* * * * *

[FR Doc. 2026–04352 Filed 3–4–26; 8:45 am]

BILLING CODE 3510–17–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 201 and 207

[Docket No. FDA–2021–N–1351]

RIN 0910–AI52

Revising the National Drug Code Format and Drug Label Barcode Requirements

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is issuing a final rule to standardize the format of the National Drug Code (NDC). Under this final rule, all FDA-assigned NDCs will be required to be 12 digits in length with 3 distinct segments and 1 uniform format. The first segment is a 6-digit labeler code, the second segment is a 4-digit product code, and the third segment is a 2-digit package code. Additionally, we are revising the drug product barcode label requirements to permit the use of other data carriers that meet the standards of this final rule.

DATES: This rule is effective March 7, 2033.

ADDRESSES: For access to the docket to read background documents or comments received, go to *https://www.regulations.gov* and insert the docket number found in brackets in the heading of this final rule into the ''Search'' box and follow the prompts, and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852–0001, 240–402–7500.

FOR FURTHER INFORMATION CONTACT:

With regard to the aspects of the final rule pertaining to human drug products: Leyla Rahjou-Esfandiary, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 2262, Silver Spring, MD 20993–0002, 301–796–3185, *leyla.rahjou-esfandiary@fda.hhs.gov.*

With regard to the aspects of the final rule pertaining to human biological products: Phillip Kurs, Center for Biologics Evaluation and Research, Food and Drug Administration, 240–402–7911, *Phillip.Kurs@fda.hhs.gov.*

With regard to the aspects of the final rule pertaining to animal drug products: Charise Kasser, Center for Veterinary Medicine, Food and Drug Administration, 240–402–6816, *charise.kasser@fda.hhs.gov.*

With regard to the information collection: Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852–2766, 301–796–5733, *PRAStaff@fda.hhs.gov.*

SUPPLEMENTARY INFORMATION:

Table of Contents

I. Executive Summary

A. Purpose of the Final Rule

FDA is modifying our regulations to establish a uniform, 12-digit format for the NDC (21 CFR 207.33). FDA's transition to a uniform format for FDA-assigned NDCs is intended to facilitate the adoption of a single NDC format across the entire healthcare industry, eliminating the need to convert NDCs from one of FDA's prescribed formats to a different standardized format used by other sectors of the healthcare industry (*e.g.,* healthcare providers and payors). FDA is also revising the drug product barcode label requirements (21 CFR 201.25) to allow the use of either linear or nonlinear barcodes, so long as the barcode format conforms to certain standards and is recognized by FDA.

B. Summary of the Major Provisions of the Final Rule

Under this final rule, FDA is amending its regulations to adopt a uniform, 12-digit format for the NDC. Under the revised format, NDCs will continue to consist of three segments: the labeler code, the product code, and the package code. However, the labeler code will be 6 digits, the product code will be 4 digits, and the package code will be 2 digits. To provide maximum flexibility on the type of barcode used on the label of a drug product, this final rule allows the use of either linear or nonlinear barcodes, so long as the barcode format conforms to certain standards and is recognized by FDA.

On the effective date of this final rule, FDA will begin assigning new NDCs in the uniform, 12-digit format, and existing 10-digit NDCs assigned by FDA prior to the effective date will be required to convert to the uniform 12-digit NDC format.[1] As a result, all

[1] FDA considers the conversion of a 10-digit NDC assigned by FDA prior to the effective date to the new, uniform 12-digit NDC format to be a ministerial, administrative change and not the assignment of a ''new'' NDC. Furthermore, FDA considers such an NDC in its original 10-digit format and in its converted 12-digit format to be the same NDC with different formats. A drug product that was originally assigned a 10-digit NDC prior to the effective date would be considered to have a new NDC only if it were assigned a new NDC by FDA after the effective date (*e.g.,* pursuant to a request for a new NDC because there was change

Continued